GlassScriptPhysician profile
Manjulatha Badam
NPI 1417013368
$1,191.90
in general payments reported to CMS, 2019-2025
10 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Undersea and Hyperbaric Medicine (Preventive Medicine) provider received nationally (typical 2025 total: $210).
See the full distribution for Undersea and Hyperbaric Medicine (Preventive Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $50.20 · 2021: $179 · 2022: $301 · 2023: $151 · 2024: $157 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $599.54 | 2019-2024 | Puraply |
| Smith+Nephew, INC. | $169.88 | 2021-2024 | Renasys Go V2 Home, Grafix Pl |
| Revance Therapeutics, INC. | $139.20 | 2025 | Daxi |
| Blueprint Medicines Corporation | $86.52 | 2025 | |
| Misonix INC | $63.59 | 2019 | |
| Tactile Systems Technology INC | $42.44 | 2019-2024 | Entre Plus, Flexitouch Plus |
| Medline Industries LP | $30.49 | 2021 | |
| Convatec INC. | $28.56 | 2021-2022 | |
| Osiris Therapeutics INC. | $18.03 | 2019 | |
| Hydrofera LLC | $13.65 | 2024 | Cutimed Sorbion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjulatha Badam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.